Document is current
Any future updates will be listed below
-
Authors
Núñez, Julio
Miñana, Gema
Villalonga, Maria
Asenjo, María
Carrera, Margarita
Epelde, Francisco
Gil, Mercè
Chivite, David
Contra, Anna
Pla, Xavi
Casado, Jesús
Miró, Òscar
de la Espriella, Rafael
Testani, Jeffrey M
Trullàs, Joan Carles https://orcid.org/0000-0002-7380-3475
,
Salamanca-Bautista, Prado
Ruiz-Hueso, Rocío
Domingo, Soraya
Núñez, Ma Victoria
Olmedo, Jesús
Vázquez, Carmen
López, Juan Bosco
Peinado, Alejandro
Montes, Juan Antonio
Díez-Manglano, Jesús
Martínez-Rodés, Pablo
Garcés, Vanesa
Rubio, Jorge
Fernández-Rodríguez, José María
Argüelles-Curto, Adrián
Torrallardona-Murphy, Orla
Gavà-Manso, Meritxell
Conde-Martel, Alicia
García, José Ma
González, Sonia
Dávila, Melitón F.
Hernández, Rubén
Gudiño, Diego José
Mendoza, Humberto
Sánchez-Biosca, Anna
Becerra, Raquel
Massi, Paulina Ivanova
Formiga, Francesc
Núñez, Raquel
Pacho, Cristina
Ceresuela, Luis
Morales, José Luís
López, Gabriel
Blázquez, Julio
López-Reboiro, Manuel Lorenzo
Castro, José López
Peralta, Paula
Llàcer, Pau
Manzano, Luis
Ruiz-Ortega, Raúl Antonio
Vázquez, Miguel Ángel
Soler, Llanos
Mesado, Daniel
Abad, Daniel
Peláez-Ballesta, Ana Isabel
Morcillo-Rodríguez, Elena
-
Funding
Funding for this research was provided by:
Centro de Investigación Biomédica en Red Enfermedades Cardiovasculares (CIBER-CV 16/11/00420)
- License Information
-
More Information
Article History
Received: 11 February 2025
Accepted: 26 April 2025
First Online: 17 May 2025
Declarations
:
: JN reports personal fees or advisory boards from Alleviant, AstraZeneca, Boehringer Ingelheim, Bayer, Novartis, NovoNordisk, Pfizer, Rovi, and Vifor Pharma (outside the submitted work). J.M.T. reports grants and/or personal fees from 3ive labs, Bayer, Bristol Myers Squibb, Astra Zeneca, Novartis, Cardionomic, Reprieve inc., FIRE1, W.L. Gore, Sanofi, Sequana Medical, Otsuka, Abbott, Merck, Windtree Therapeutics, Lexicon pharmaceuticals, Precardia, Relypsa, Regeneron, BD, Edwards life sciences, Lilly and Corteria pharmaceuticals. In addition, J.M.T. has a patent for Treatment of diuretic resistance issued to Yale and Corvidia Therapeutics and a patent Treatment of diuretic resistance with Reprieve inc. The rest of the authors do not have any conflicts of interest.
: The study was carried out in accordance with the Declaration of Helsinki. The study was approved by a central committee, the Clinical Research Ethics Committee of the Dr. Josep Trueta University Hospital in Girona (Spain), by the Ethics Committees of the participating centres, and by the Spanish Agency Medicines and Health Products (AEMPS in the Spanish acronym).
: The study was also registered in clinicaltrials.gov (Identifier: NCT04740242). An informed consent was obtained from all participating subjects.
